Farther Finance Advisors Boosts Bristol Myers Squibb Holdings

Investment firm increases stake in pharmaceutical company by over 100%

Apr. 18, 2026 at 7:59am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other industrial components that make up the inner workings of a financial institution, conveying the idea of the complex machinery behind the pharmaceutical industry.Farther Finance Advisors' increased investment in Bristol Myers Squibb signals confidence in the pharmaceutical company's ability to navigate the complex financial and regulatory landscape.Princeton Today

Farther Finance Advisors LLC, a financial advisory firm, has significantly increased its holdings in Bristol Myers Squibb Company (NYSE: BMY), a major biopharmaceutical company. According to a recent SEC filing, Farther Finance Advisors lifted its position in Bristol Myers Squibb by 108.6% in the fourth quarter, now owning 78,283 shares worth $4.22 million.

Why it matters

This investment move by Farther Finance Advisors suggests the firm sees strong potential in Bristol Myers Squibb's business and future prospects. As a major player in the pharmaceutical industry, Bristol Myers Squibb's performance is closely watched by investors and analysts.

The details

Farther Finance Advisors' increased stake in Bristol Myers Squibb comes as the biopharmaceutical company continues to advance its pipeline of cancer and immune-mediated treatments. The firm now owns 78,283 shares of Bristol Myers Squibb, up from 37,527 shares held in the prior quarter. This represents a significant 108.6% increase in Farther Finance Advisors' position in the company.

  • Farther Finance Advisors increased its Bristol Myers Squibb holdings in the 4th quarter of 2025.
  • The firm's latest 13F filing, disclosing the increased stake, was published on April 18, 2026.

The players

Farther Finance Advisors LLC

A financial advisory firm that has significantly increased its investment in Bristol Myers Squibb.

Bristol Myers Squibb Company

A major biopharmaceutical company focused on developing and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

Got photos? Submit your photos here. ›

The takeaway

This investment move by Farther Finance Advisors highlights the continued investor interest and confidence in Bristol Myers Squibb's ability to deliver innovative treatments and drive growth in the competitive pharmaceutical industry.